Biobide takes part in a research about Malaria funded by Melinda and Bill Gates

Biobide (Bionaturis Group) has recently participated in a drug discovery research against malaria, a disease that causes about 440,000 deaths each year worldwide. The collaborative international project supported by Melinda and Bill Gates has the main goal of going from Hits to Leads among a selection of 400 compounds –included in the Malaria Box- to which researchers from 30 different countries have had access in the lastest two years. The final end is public institutions and the industry sharing more open knowledge in order to progress in new joint developments.

The promising results have just been published in a scientific paper and include the toxicity assays in zebrafish performed by Biobide to test the potential toxicity of the candidates to fight malaria. “Our presence in this study shows the versatility and usefulness of the zebrafish as animal model for drug discovery, as well as our expertise in this field. In addition to the obvious scientific value, this collaborative project has also a very relevant social value for Biobide, that is contributing in this way to find solutions for a disease that affected 95 countries worldwide in 2015”, the R&D Management Director at Biobide, Arantza Muriana, has stated.

In the 290 assays made by the different researchers for this study, 130 compounds have shown potential action against malaria which paves the way for a future election of the most suitable ones to develop new drugs. Additionally, some of these compounds have also shown outstanding activity against other disease agents, including bacteria, fungi, other parasites and even human cancer cells. In fact, these positive results have ignited over 30 drug development program devoted to fight different diseases. This initiative has been so satisfying that promoters are already repeating […]

August 2nd, 2016|Blog english|Comments Off|

Biotechnology bets on vaccines

The research on vaccines has found a great partner in biotechnology. Nowadays, 30 out of 80 biological products in latest stages of clinical development are biological vaccines to fight currently unmet diseases. According to BIOTECH MAGAZINE, while in Asia and South America the great concern are diseases such as dengue, in Western countries the infections acquired in hospitals (called nosocomial infections) are becoming an increasing problem.

In this way, Bionaturis is taking part in the public-private consortium Adelis, looking for alternatives to traditional antibiotics to tackle the more and more common phenomena of resistance.

Tuberculosis, AIDS, malaria, and leishmaniasis, among others, are diseases for what biotechnology is actively looking for solutions. Hence, Bionaturis is developing a recombinant vaccine against canine visceral leishmaniasis that has already shown efficacy and safety in mice and beagle dogs.

For further information on biotechnology advances on vaccines, please click here

March 25th, 2014|Blog english|0 Comments|

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.